Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect

We expect Fusion Pharmaceuticals (FUSN) to beat expectations when it reports first-quarter 2024 results. Without a marketed product, investors will focus on the upcoming earnings call for updates regarding Fusion’s pipeline candidates.In March 2024, Fusion signed a definitive agreement with AstraZeneca (AZN) , where the latter will acquire all outstanding shares of FUSN for $21 per share in cash, aggregating to $2 billion.The transaction is expected to close in the second quarter of 2024, subject to customa ...